A New Hypothesis: Possible Mechanisms in the Involvement of the Increased Plasminogen Activator Activity in Branching Regions of the Aorta in the Initiation of Atherosclerosis

A Smokovitis

doi:10.1055/s-0038-1650036

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1980; 43(02): 141-146
DOI: 10.1055/s-0038-1650036

Original Article

Schattauer GmbH Stuttgart

A New Hypothesis: Possible Mechanisms in the Involvement of the Increased Plasminogen Activator Activity in Branching Regions of the Aorta in the Initiation of Atherosclerosis

A Smokovitis

The Gaubius Institute, Health Research Organization TNO, Leiden, The Netherlands; Department of Physiology, School of Medicine, University of Vienna, Vienna, Austria

› Author Affiliations

Abstract

PDF Download

Summary

Branching regions of the aorta are predilection regions for atherosclerosis. The intima in the branching regions of the normal aorta shows a constantly increased plasminogen activator activity from early life. At these areas, the endothelium is also damaged, it shows increased permeability, etc. The constantly increased plasminogen activator activity (local plasmin production) might play a protective role or on the contrary might participate in the initiation of atherosclerosis at the branching regions through a number of proved or suggested mechanisms.

No matter what the actual role of the locally increased plasminogen activator activity in the initiation of atherosclerosis is, the role of the fibrinolytic system in the progression of the atherosclerotic lesion seems to be clear. There is an accumulation of evidence that the impaired fibrinolytic activity in atherosclerotics participates in the progression and the complications of the disease.

Keywords

Atherosclerosis - Branching regions - Plasminogen activator - Plasmin - Initiation of atherosclerosis - Progression of atherosclerosis - Fibrinolysis

PDF (1333 kb)

References

References
1 Smokovitis A. Regions of constantly increased plasminogen activator activity along the intima of the normal aorta. Haemostasis 1978; 7: 303-319
2 Glas-Greenwalt P. Latent and manifest endothelial fibrinolysis. Third Int Congr on Thrombosis and Haemostasis, Washington D C, 1972 (Abstr 290); personal communication
3 Noordhoek HegtV. Distribution and variation of fibrinolytic activity in the walls of human arteries and veins. Haemostasis 1976; 5: 355-372
4 Astrup T, Albrechtsen OK, Claessen M, Rasmussen J. Thrombo-plastic and fibrinolytic activity of the human aorta. Circulation Res 1959; 7: 969-976
5 Donner L, Klener P, Roth Z. The plasminogen activator of the arterial wall. Thromb Haemost 1977; 37: 436-443
6 Onoyama K, Tanaka K. Fibrinolytic activity of the arterial wall. Thromb Diath haemorrh 1969; 21: 1-11
7 Pelczar ME, Glas-Greenwalt P, Astrup T. Primary pulmonary aspergillosis with high fibrinolytic activity in the aortic intima. Chest 1972; 61: 394-396
8 Smokovitis A, Binder BR. The effect of alloxan-induced diabetes on tissue plasminogen activator activity of the rat. Thromb Haemost 1979; 42: 333 (Abstr); paper in preparation
9 Smokovitis A, Auerswald W, Binder BR. Induced changes in the endothelial plasminogen activator activity of the rat aorta. Fifth Meeting of the International Society of Haematology, Hamburg 1979; Vol 2 p 48 (Abstr)
10 Smokovitis A, Binder BR. Wirkung des anabolen Steroids Stanozolol auf die fibrinolytische Aktivität bei der Ratte. I Kongreß für Thrombose und Blutgerinnung. Schattauer Verlag (in press); Blut: 1980. 40 174 (Abstr). Experientia 1980 (in press)
11 Smokovitis A, Auerswald W, Binder BR. Endothelzellen-Plasminogen-Aktivator-Aktivität (PAA) bei genetisch hypercholesterinämischen Ratten (RICO); Wirkung von Streptozotocin auf die Endothelzell-PAA. I Kongreß für Thrombose und Blutgerinnung. Schattauer Verlag (in press); Blut: 1980. 40 173 (Abstr)
12 Smokovitis A, Auerswald W, Binder BR. Wechselwirkung zwischen Streptozotocin und Dexamethason auf die Plasminogen-Aktivator-Aktivität (PAA) des Endothels der Rattenaorta. I Kongreß für Thrombose und Blutgerinnung. Schattauer Verlag (in press); Blut: 1980. 40 176 (Abstr)
13 Björkerud S, Bonjers G. Endothelial integrity and viability in the aorta of the normal rabbit and rat as evaluated with dye exclusion tests and interference contrast microscopy. Atherosclerosis 1972; 15: 285-300
14 Gutstein WH, Farrell GA, Armellini C. Blood flow disturbance and endothelial cell injury in preatherosclerotic swine. Lab Invest 1973; 27: 134-149
15 Reidy MA, Bowyer DE. Scanning electron microscopy of arteries. The morphology of aortic endothelium in haemodynamically stressed areas associated with branches. Atherosclerosis 1977; 26: 181-194
16 Wright HP. Endothelial mitosis around aortic branches in normal guinea-pigs. Nature 1968; 220: 78-79
17 Wright HP. Endothelial turnover. Thromb Diath haemorrh suppl 1970; 40: 79-84
18 Wright HP. Areas of mitosis in aortic endothelium of guinea-pigs. J Path 1971; 105: 65-67
19 Wright HP. Mitosis patterns in aortic endothelium. Atherosclerosis 1972; 15: 93-100
20 Schwartz SM, Benditt EP. Cell replication in the aortic endothelium. A new method for study of the problem. Lab Invest 1973; 28: 699-707
21 Jørgensen L, Packham MA, Rowsell HC, Mustard JF. Deposition of formed elements of blood on the intima and signs of intimal injury in the aorta of rabbits, pigs, and man. Lab Invest 1972; 27: 341-350
22 Florentin RA, Nam SC, Lee KT, Lee KJ, Thomas WA. Increased mitotic activity in aortas of swine. Arch Path 1969; 88: 463-469
23 Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell. Science 1973; 180: 1332-1339
24 Packham MA, Rowsell HC, Jørgensen L, Mustard JF. Localized protein accumulation in the wall of the aorta. Exper Mol Path 1967; 7: 214-232
25 Somer JB, Schwartz CJ. Focal ³H-cholesterol uptake in the pig aorta. Atherosclerosis 1971; 13: 293-304
26 Bell FP, Somer JB, Craig IH, Schwartz CJ. Patterns of aortic evans blue uptake in vivo and in vitro. Atherosclerosis 1972; 16: 369-375
27 Bell FP, Adamson IL, Schwartz CJ. Aortic endothelial permeability to albumin: Focal and regional patterns of uptake and transmural distribution of ¹³¹I-albumin in the young pig. Exper Mol Path 1974; 20: 57-68
28 Bell FP, Gallus AS, Schwartz CJ. Focal and regional patterns of uptake and the transmural distribution of ¹³¹I-fibrinogen in the pig aorta in vivo. Exper Mol Path 1974; 20: 281-292
29 Caplan BA, Gerrity RG, Schwartz CJ. Endothelial cell morphology in focal areas of in vivo evans blue uptake in the young pig aorta. I Quantitative light microscopic findings. Exper Mol Path 1974; 21: 102-117
30 Giacomelli F, Wiener J. Regional variation in the permeability of rat thoracic aorta. Amer J Path 1974; 75: 513-521
31 Katora ME, Hollis TM. Regional variation in rat aortic endothelial surface morphology: Relationship to regional aortic permeability. Exper Mol Path 1976; 24: 23-34
32 Fry DL. Certain chemorheologic considerations regarding the blood vascular interface with particular reference to coronary artery disease. Circulation 1969; 39 Suppl 4 38-57
33 Caro CG, Fitz-Gerald JM, Schroter RC. Wall shear rate in arteries and distribution of early atheroma. Thromb Diath haemorrh 1970; Suppl 40: 111-116
34 Texon M. The hemodynamic basis of atherosclerosis. Further observations. The ostiai lesion. Bull NY Acad Med 1972; 48: 733-740
35 Gessner FB. Hemodynamic theories of atherogenesis. Circulation Res 1973; 33: 259-265
36 Rodkiewicz CM. Some aspects of the arterial blood flow. University of Alberta, Edmonton: 1976
37 Lindsay S, Chaikoff IL. Naturally occurring arteriosclerosis in animals: A comparison with experimentally induced lesions. In: Atherosclerosis and its origin. (Eds Sandler M, Bourne GH. Academic Press, New York: 1963. p 349
38 Roberts JC, Straus R, Cooper MC. (Eds) Comparative atherosclerosis. Harper and Row, Publish, New York: 1965
39 Zahor Z, Czabanova V. Experimental atherosclerosis of the heart valves in rat following a long-term atherogenic regimen. Atherosclerosis 1977; 27: 49-57
40 Fuchs U, Jobst M, Gepp G, Gottschild D. Arterial permeability to labeled protein. Progr Biochem Pharmacol 1977; 14: 161-163
41 Adams CW M. J Clin Path 1973; 26 (Suppl 5) 38
42 Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Amer J Path 1977; 86: 675-684
43 Mustard JF. Thrombosis and arterial disease. In: Venous and Arterial Thrombosis, pathogenesis, diagnosis, prevention, and therapy. (Eds. Joist JH, Sherman LA. Grune and Stratton, Inc, New York: 1979. pp 207-223
44 Kadish JL. Fibrin and atherogenesis – A hypothesis. Atherosclerosis 1979; 33: 409-413
45 Astrup T. Pathophysiology of the fibrinolytic system and the pathogenesis of arteriosclerosis. Minerva Cardioangiologica 1974; 22: 5
46 Pearson TA, Dillman J, Solez K, Heptinstall RH. Monoclonal characteristics of organising arterial thrombi. Significance in the origin and growth of human atherosclerotic plaques. Lancet 1979; 1: 7-11
47 Copley AL. Fibrin(ogen), platelets and a new theory of atherogenesis. Thromb Res 1979; 14: 249-263
48 Reich E. Tumor-associated fibrinolysis. Federation Proc 1973; 32: 2174-2175
49 McNicol GP, Douglas AS. The fibrinolytic enzyme system. In: Human blood coagulation, Haemostasis, and Thrombosis. Biggs R. Blackwell Scientific Publ: 1976. pp 399-435
50 Blumberg PM, Robbins PW. Effect of proteases on activation of resting chick embryo fibroblasts and on cell surface proteins. Cell 1975; 6: 137-147
51 Lazarowitz SG, Goldberg AR, Choppin PW. Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: Host cell activation of serum plasminogen. Virology 1973; 56: 172-180
51a Greenberg IP, Packham MA, Guccione MA, Rand ML, Reimers HI, Mustard IF. Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood 1979; 53: 916-927
52 Klynstra FB, Böttcher CJ F. Permeability patterns in pig aorta. Atherosclerosis 1970; 11: 451-462
53 Klynstra FB. On the passage-restricting role of acid mucopolysaccharides in the endothelium of pig aortas. Atherosclerosis 1974; 19: 215-220
54 Bray BA, Hsu KC, Wigger HJ, Le Roy EC. Association of fibrinogen and microfibrils with trophoblast basement membrane. Connect Tissue Res 1975; 3: 55-71
55 Martinez-Hernandez A, Fink LM, Pierce GB. Lab Invest 1976; 34: 455
56 Reich E. Plasminogen activator: Secretion by neoplastic cells and macrophages. In: Proteases and Biological Control.. (Eds Reich E, Rifkin DB, Shaw W. ) Cold Spring Harbor Lab: 1975. 2: 333-341
57 Beers WH. Follicular plasminogen and plasminogen activator and the effect of plasmin on ovarian follicle wall. Cell 1975; 6: 379-386
58 Beers WH, Strickland S, Reich E. Ovarian plasminogen activator: Relationship to ovulation and hormonal regulation. Cell 1975; 6: 387-394
59 Strickland S, Beers WH. Studies on the role of plasminogen activator in ovulation. J Biol Chem 1976; 251: 5694-5702
60 Kucherlapati R, Tepper R, Granelli-Piperno A, Reich E. Modulation and mapping of a human plasminogen activator by cell fusion. Cell 1978; 15: 1331-1340
61 Ossowski L, Biegel D, Reich E. Mammary plasminogen activator: Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979; 16: 929-940
62 Werb Z, Mainardi CL, Vater CA, Harris ED. Endogenous activation of latent collagenase by rheumatoid synovial cells. N Engl J Med 1977; 296: 1017-1023
63 Sawyer PN. Effect of brinase and thrombolysin on the electrochemical nature of the cardiovascular system of experimental animals (dogs and rabbits). Thromb Res 1977; 10: 531-536
64 Jones R, Vesselinovitch D, Wissler RW. Ultrastructural changes in aortas of Rhesus monkeys during reversal of atherosclerotic lesions. Amer J Path 1973; 70: 88-89
65 Weber G, Fabbrini P, Resi L, Jones R, Vesselinovitch D, Wissler RW. Regression of atherosclerotic lesions in Rhesus monkey aortas after regression diet. Atherosclerosis 1977; 26: 535-547
66 Ratnoff OD. Increased vascular permeability induced by human plasmin. J Exp Med 1965; 122: 905-921
67 Malofiejew M. The biological and pharmacological properties of some fibrinogen degradation products. Scand J Haematol 1971; 8 (suppl 13) 303-310
68 Gerdin B, Saldeen T. Effect of fibrin degradation products on microvascular permeability. Thromb Res 1978; 13: 995-1006
69 Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Nat Acad Sci USA 1973; 70: 1753-1756
70 Benditt EP. Evidence for a monoclonal origin of human atherosclerotic plaques and some implications. Circulation 1974; 50: 650-652
71 Benditt EP. Implications of the monoclonal character of human atherosclerotic plaques. Ann NY Acad Sci 1976; 275: 96-103
72 Benditt EP. Implications of the monoclonal character of human atherosclerotic plaques. Amer J Path 1977; 86: 693-702
73 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369-377 and 420-425
74 Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Nat Acad Sci USA 1974; 71: 1207-1210
75 Rutherford RB, Ross R. Platelet factors stimulate fibroblasts and smooth muscle cells. Quiscent in plasma serum to proliferate. J Cell Biol 1976; 69: 196-203
76 Harker LA, Ross R, Glomset J. Role of the platelet in atherogenesis. Ann NY Acad Sci 1976; 275: 321-329
77 Roensch LF, Blohm TR. Interactions of lipoproteins with cells in culture. In: Low density lipoproteins. Day C E and Levy RS. Plenum Press, New York: 1976. pp 93-110
78 Kolata GB. Atherosclerotic plaques: Competing theories guide research. Science 1976; 194: 592-594
79 Larrieu MJ, Dray L, Ardaillou N. Biological effects of fibrinogenfibrin degradation products. Thromb Diath haemorrh 1975; 34: 686-692
80 Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. J Clin Invest 1973; 52: 1647-1659
81 Hanson S, Harker LA. Simultaneous ⁵¹Cr and ¹⁴C-serotonin platelet survival measurements. Thromb Haemost 1977; 38: 140
82 Niewiarowski S, Gurewich V, Senyi AF, Mustard JF. The effect of fibrinolysis on platelet function. Thromb Diath haemorrh 1971; (Suppl 47) 99-110
83 Joist JH. Platelets and fibrinolysis. Thromb Haemost 1977; 38: 955-961
84 Loskutoff DJ, Paul D. Intracellular plasminogen activator activity in growing and quiscent cells. J Cell Physiol 1978; 97: 9-16
85 Gospodarowicz D, Greenberg G, Bialecki H, Zetter BR. Factors involved in the modulation of cell proliferation in vivo and in vitro: The role of fibroblast and epidermal growth factors in the proliferative response of mammalian cells. In Vitro 1978; 14: 85-118
86 Bernik MB, Oiler EP. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 1973; 52: 823-834
87 Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-550
88 Lipinski B, Gurewich V. α₂-plasmin inhibitor deficiency. Lancet 1979; 1: 329
89 Müllertz S. The fibrinolytic system. Scand J Haematol 1979; (Suppl 34) 15-23
90 Chesterman CN, Allington MJ, Sharp AA. Relationship of plasminogen activator to fibrin. Nature New Biology 1972; 238: 15-17
91 Shainoff JR, Page IH. Deposition of modified fibrinogen within the aortic intima. Atherosclerosis 1972; 16: 287-305
92 Smith EB, Alexander KM, Massie IB. Insoluble "fibrin" in human aortic intima. Quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoprotein. Atherosclerosis 1976; 23: 19-39
93 Smith EB. Molecular interactions in human atherosclerotic plaques. Amer J Path 1977; 86: 665-674
93a Gordon S. Macrophage neutral proteinases and defense of the lung. Fed Proc 1977; 36: 2707-2711
94 Chandler AB, Pope JT. Arterial thrombosis in atherogenesis. In: Blood and arterial wall in atherogenesis and arterial thrombosis. Hautvast JG A J, Hermus R J J and Van Der HaarF. Leiden, E J Brill: 1975. pp 111-118
95 Smith EB, Staples EM, Dietz HS. Role of endothelium in sequestration of lipoprotein and fibrinogen in aortic lesions, thrombi, and graft pseudo-intimas. Lancet 1979; 2: 812-816
96 Morgan AD. The pathogenesis of coronary occlusion. Oxford, Blackwell Scientific Publ: 1956. p 171
97 Haust MD, Movat HZ, More RH. The role of fibrin thrombi in the genesis of the common white plaque in atherosclerosis. Circulation 1956; 14: 483
98 Burleson RL, Ennulat N. Fibrin adherence to biologic tissues. J Surg Res 1978; 25: 523-529
99 Chakrabarti R, Hocking ED, Fearnley GR, Mann RD, Attwell TN, Jackson D. Fibrinolytic activity and coronary-artery disease. Lancet 1968; 1: 987-990
100 Sikka KK, Navani H, Tiagi GK, Nigam DN. Blood coagulation and fibrinolysis in relation to coronary artery disease. Ind J Med Res 1968; 56: 411-415
101 Peabody RA, Tsapogas MJ, Wu Kwang-Tzen, Deveraj KT, Karmody AM, Eckert C. Altered endogenous fibrinolysis and biochemical factors in atherosclerosis. Arch Surg 1974; 109: 309-313
102 Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. Impairment of the diurnal fibrinolytic response in man: Effects of aging, type IV hyperlipoproteinemia, and coronary artery disease. Circulation Res 1973; 32: 752-758
103 Hart HC. The biological half-life of I¹³¹-fibrinogen. Thesis. Schriks' Drukkerij N V, Asten N-Br. The Netherlands 1966
104 D'Angelo V, Villa S, Donati MB, De Gaetano G. Defective fibrinolytic and prostacylcin-like activity in human atheromatous plaques. Thromb Haemost 1978; 39: 535-536
105 Sinzinger H, Feigl W, Silberbauer K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979; 2: 442-443
106 Sinzinger H, Silberbauer K, Feigl W, Wagner O, Winter M, Auerswald W. Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb Haemost 1979; 42: 803-804
107 Noordhoek HegtV. Localization and distribution of fibrinolysis inhibition in the walls of human arteries and veins. Thromb Res 1977; 10: 121-135
108 Kwann HC, Astrup T. Fibrinolytic activity in human atherosclerotic coronary arteries. Circulation Res 1967; 21: 799-804
109 Sarkar N. Reduced fibrinolytic activity of atherosclerotic sera caused by an increase in low-density lipoproteins in blood. Nature 1961; 189: 929-931
110 Naimi S, Goldstein R, Proger S. Studies of coagulation and fibrinolysis of the arterial and venous blood in normal subjects and patients with atherosclerosis. Circulation 1963; 27: 904-918
111 Chakrabarti R, Fearnley GR, Hocking ED, Delitheos A, Clarke GM. Fibrinolytic activity related to age in survivors of myocardial infarction. Lancet 1966; 1: 573
112 Loncin H, Gurian JM, Loncin ME. Blood coagulation, fibrinolysis and coronary heart disease: Observations in Malaysia. J Atheroscler Res 1968; 8: 471-482
113 Spöttl F, Holzknecht F, Knapp E, Steinmetz U, Braunsteiner H. A basic study on the global coagulation and fibrinolysis of hyper-lipaemic and atherosclerotic patients. Atherosclerosis 1970; 12: 427-437
114 Browse NL, Gray L, Jarrett PE M, Morland M. Blood and vein-wall fibrinolytic activity in health and vascular disease. Brit Med J 1977; 1: 478-481
115 Wilkens HJ, Back N. Fibrinolysis and risk factors of atherosclerotic disease, with special emphasis on diabetes mellitus. Circul Shock 1978; 5: 125-143
116 Meade TW, Chakrabarti R, Haines AP, North WR S, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Brit Med J 1979; 1: 153-156
117 Naimi S, Proger S. Fibrinolytic activity and coronary artery disease. Lancet 1968; 1: 1250-1251
118 Constantini R, Hilbe G, Spöttl F, Holzknecht F. The plasminogen activator content of the arterial wall in occlusive arterial disease. Thromb Diath haemorrh 1972; 27: 649-654
119 Walker ID, Davidson JF, Hutton I, Lawrie TD V. Disordered "fibrinolytic potential" in coronary heart disease. Thromb Res 1977; 10: 509-520
120 Bielawiec M, Mysliwiec M, Perzanowski A. Combined therapy with phenformin plus stanozolol in patients with occlusive arterial disease and recurrent venous thrombosis. Third Int Conf on Synthetic fibrinolytic thrombolytic agents, Glasgow 1976; (Abstr 44). In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. Raven Press, New York: 1978. 3: 507-512
121 Bielawiec M, Mysliwiec M, Perzanowski A. Long-term enhancement of fibrinolysis in patients with arteriosclerosis and recurrent venous thrombosis. First Florence Conf on Haemostasis and Thrombosis, Florence 1977 p 181
122 Dupuy E, Fleming AF, Caen JP. Platelet function, factor VIII, fibrinogen, and fibrinolysis in Negerians, and Europeans in relation to atheroma and thrombosis. J Clin Path 1978; 31: 1094-1101
123 Lancet (editorial) Oestrogens and atheroma. Lancet 1978; 2: 508-510